Researchers identify possible receptor for key breast cancer regulator

A key protein potentially involved in regulating breast cancer progression has been identified by researchers at Clarkson University in Potsdam, N.Y. Led by professor Costel Darie, the team worked to identify the binding partner of Tumor Differentiating Factor (TDF), a pituitary hormone that had previously been shown to reduce cancer progression in breast cancer cells.

Earlier studies had shown that treated with TDF lost their cancerous characteristics and began acting like normal mammary cells, suggesting that TDF had tumor-suppressing capabilities. However, how TDF acted remained unclear, leading Darie's group to initiate a search for a cellular receptor in cancer cells that might bind TDF and transmit its anti-tumorigenic cues.

Darie's group found that a receptor, labeled TDF-R, was found exclusively in breast, but not other cancer, cells, suggesting a level of specificity that agrees with previous reports of the efficacy of TDF. This result, which is being reported in a forthcoming issue of the , has substantial potential implications for developing new therapies for treating breast cancers known to be unresponsive to standard steroid hormone-based therapies, such as tamoxifen treatment.

Looking toward the next step, Darie asserted that "finding the receptor for the TDF hormone will allow us to rationally design drugs that will have a potent ability to stop ." He continued, "We will also be able to use TDF as a biomarker for breast cancer onset, thereby improving diagnoses."

Though and mortality rates have declined over the past 30 years, breast cancer remains a major killer: In 2007, accounted for about 40,000 deaths in the U.S., while another 200,000 women were diagnosed, according to the Center for Disease Control.

More information: The Journal of Biological Chemistry, 287, 1719-1733. doi: 10.1074/jbc.M111.284091

Provided by American Society for Biochemistry and Molecular Biology

not rated yet

Related Stories

Breast cancer type linked to paternal cancer

Nov 28, 2011

The risk of breast cancer is increased by genetic and lifestyle factors such as the inherited BRCA2 gene, age of having first child, or use of hormone replacement therapy (HRT). New research published in BioMed Central's ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

5 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

9 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

Immunotherapy set to revolutionise cancer treatment

11 hours ago

Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.